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Abstract
G protein-coupled receptor 54 (GPR54) is a Gq/11-coupled 7 transmembrane-spanning receptor (7TMR). Activation of GPR54
by kisspeptin (Kp) stimulates PIP2 hydrolysis, Ca
2+ mobilization and ERK1/2 MAPK phosphorylation. Kp and GPR54 are
established regulators of the hypothalamic-pituitary-gonadal (HPG) axis and loss-of-function mutations in GPR54 are
associated with an absence of puberty and hypogonadotropic hypogonadism, thus defining an important role of the Kp/
GPR54 signaling system in reproductive function. Given the tremendous physiological and clinical importance of the Kp/
GPR54 signaling system, we explored the contributions of the GPR54-coupled Gq/11 and b-arrestin pathways on the
activation of a major downstream signaling molecule, ERK, using Gq/11 and b-arrestin knockout mouse embryonic
fibroblasts. Our study revealed that GPR54 employs the Gq/11 and b-arrestin-2 pathways in a co-dependent and temporally
overlapping manner to positively regulate ERK activity and pERK nuclear localization. We also show that while b-arrestin-2
potentiates GPR54 signaling to ERK, b-arrestin-1 inhibits it. Our data also revealed that diminished b-arrestin-1 and -2
expression in the GT1-7 GnRH hypothalamic neuronal cell line triggered distinct patterns of gene expression following Kp-
10 treatment. Thus, b-arrestin-1 and -2 also regulate distinct downstream responses in gene expression. Finally, we showed
that GPR54, when uncoupled from the Gq/11 pathway, as is the case for several naturally occurring GPR54 mutants
associated with hypogonadotropic hypogonadism, continues to regulate gene expression in a G protein-independent
manner. These new and exciting findings add significantly to our mechanistic understanding of how this important receptor
signals intracellularly in response to kisspeptin stimulation.
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Introduction
G protein-coupled receptor 54 (GPR54) is a Gq/11coupled 7
transmembrane-spanning receptor (7TMR). Activation of GPR54
by kisspeptin (Kp) stimulates PIP2 hydrolysis, Ca
2+ mobilization,
arachidonic acid release, and ERK1/2 and p38 MAPK
phosphorylation [1]. Kp and GPR54 are established regulators
of the hypothalamic-pituitary-gonadal axis [2,3] and loss-of-
function mutations in GPR54 are associated with an absence of
puberty and hypogonadotropic hypogonadism, a condition
characterized by an absence of sexual maturation and low levels
of gonadotropic hormones (LH and FSH), in humans. Mice with
targeted deletions of GPR54 also have a hypogonadotropic
phenotype, confirming the important role of the Kp/GPR54
signaling system in the control of puberty and reproductive
function. Given the clinical importance of GPR54, we recently
conducted a study that examined the role of GPCR serine/
threonine kinase (GRK) 2 and b-arrestin in regulating GPR54
signaling [4]. In that study, we demonstrated that GRK2
stimulates the homologous desensitization of GPR54 and that b-
arrestin-2 mediates GPR54 activation of ERK1/2.
Traditionally, b-arrestins are recognized as molecules that
mediate the homologous desensitization and clathrin-dependent
endocytosis of 7TMRs [5]. However, over the past decade, b-
arrestins have been recognized to play much wider roles in biology
than previously imagined. Specifically, they serve as molecular
scaffolds for signaling proteins that couple 7TMRs to a variety of
signaling systems thereby acting as signal transducers in their own
right [6,7]. Among the signaling pathways that b-arrestins couple
7TMRs to, the ERK MAPK represents the prototype for b-
arrestin-mediated signaling. Understanding the mechanisms by
which b-arrestins activate signaling pathways like ERK1/2 is
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stream of these pathways. Such b-arrestin pathway-regulated
events include transcription, inflammation, chemotaxis, prolifera-
tion and stress fiber formation [6].
Following agonist stimulation, 7TMRs activate MAPK through
G protein-dependent mechanisms [8]. The involvement of the G
protein-dependent pathway in ERK activation was demonstrated
through the use of G protein-dependent pathway inhibitors, such
as pertussis toxin, PKC and PKA inhibitors [9–11]; G protein
pathway-uncoupled receptors and biased agonists [12–15]. For
several 7TMRs, including the Gq/11coupled proteinase-activated
receptor 2 (PAR2) and angiotensin type 1A receptor (AT1AR)
[12,16-17], the Gs-coupled b2 adrenergic receptor (b2AR) [13]
the Gq/11, Gs-coupled type I PTH/PTH-related peptide receptor
(PTH1R) [10] and the Gi-coupled dopamine D2 receptor (D2R),
G protein activation of the MAPK signal is rapid and detected
within 2-5 minutes following agonist treatment. As clearly shown
for the AT1AR, b2AR and PTH1R, G protein activation of ERK
is also transient peaking within 2-10 minutes of agonist treatment
[9–10,13,17] presumably due to the subsequent b-arrestin-
mediated desensitization of the receptor.
In a distinct but related process to the G protein-dependent
activation of ERK, b-arrestins scaffold the MAPK signaling
molecules, Raf-1, MEK1 and ERK, thereby mediating the
phosphorylation and activation of ERK 1/2 [18]. The involve-
ment of the b-arrestin-dependent pathway in ERK activation was
demonstrated through the use of b-arrestin siRNAs [9,10,12,13]
and MEFs derived from b-arrestin null mice [19]. For some
receptors, such as PAR2, b2AR and PTH1R, both b-arrestin-1
and -2 potentiate signaling to ERK [10,13,16], however,
consistent with their varied roles in regulating receptor desensi-
tization and internalization, b-arrestin-1 inhibits while b-arrestin-2
stimulates (reciprocal effect) ERK activation downstream of the
AT1AR [9].
Generally, G protein and b-arrestin-dependent ERK activation
can be resolved into two temporal phases; an early G protein-
dependent phase that is rapid and transient and a late b-arrestin-
dependent phase that is slower and more persistent, as shown for
the AT1AR, b2AR, vasopressin 2 receptor (V2R) and PTH1R
[9,10,13,20]. For these receptors, including PAR2, it has also been
shown that the G protein and b-arrestin-dependent pathways are
independent of each other and ERK activation could still be
observed if one of the pathways was blocked [9–10,13,16,20–21].
While many examples of b-arrestin-dependent signaling are G
protein-independent, some studies, such as that by Barnes et al.
[22], report that the AT1AR-dependent robust activation of RhoA
requires the cooperation of both the G protein and b-arrestin-1-
dependent pathways.
For several receptors it has been determined that activated ERK
translocates from the cytosol to the nucleus where it regulates gene
transcription. With the discovery that ERK can be activated via
the G protein and b-arrestin-dependent pathways, studies have
revealed that the eventual cellular location of activated ERK is
linked to the pathway mediating its activation. In cells expressing
PAR2 and AT1AR, ERK activated via G protein-dependent
pathway were shown to translocate to the nucleus, whereas b-
arrestin-activated ERK remained in the cytosol [6]. This pathway-
dependent cellular location requires further investigation since it
was demonstrated that b-arrestin-2 inhibited nuclear translocation
of ERK following AT1AR activation [21] but enhanced nuclear
translocation of ERK following b2AR activation [23]. These two
apparently contrasting studies suggest that the eventual cellular
location of the activated ERK is at least in part a receptor-specific
event.
Having established the role of b-arrestin-2 in coupling GPR54
to ERK [4] and given the biological importance of understanding
the mechanism by which GPR54 activates ERK, we set out to
conduct a detailed mechanistic analysis on the roles of the Gq/11
and b-arrestin-1- and -2-dependent pathways in regulating ERK
activation and gene expression following GPR54 activation. These
studies were conducted in mouse embryonic fibroblast cell lines
bearing Gq/11 and b-arrestin-1 and -2 gene deletions or
disruptions and a mouse GnRH hypothalamic cell line expressing
reduced levels of b-arrestin-1 and -2. Our results reveal that b-
arrestin-1 inhibits while b-arrestin-2 and Gq/11 activate ERK1/2
in a co-dependent manner following GPR54 activation. Our
results also reveal that b-arrestin-1 and -2 regulate distinct
downstream responses in gene expression.
Results
GPR54 is coupled to ERK MAPK pathway in WT MEFs
Using the b-arrestin-1 and -2 WT parental MEF cell lines
expressing exogenous GPR54, we determined whether there was a
functional GPR54/ERK signaling system. This was done by
treating cells with increasing concentrations of Kp-10 (1 to
1000 nM) for 10 minutes following which ERK activation was
assessed by western blotting. Ten minutes were chosen as the
treatment time since several studies conducted in a variety of
GPR54 expressing cell lines showed ERK remains highly elevated
at 10 minutes [1,24]. Our results showed that relative to HBSS
(vehicle) treated and unstimulatedcells, ERKactivationwas visually
detectable in both WT lines following 10 nM Kp-10 stimulation
(Fig. 1A–D). As Kp-10 concentration increased so did pERK levels
with activation leveling off at 100 nM Kp-10 (Fig. 1A–D). Next, we
conducted a time-course study in which GPR54 overexpressing b-
arrestin-1 and -2 WT parental MEF cell lines were treated with
100 nM Kp-10 for 5, 10, 30 and 60 minutes following which ERK
activation was assessed by western blotting. Our results revealed
that in both WT parental MEFs, ERK was activated rapidly (within
5 minutes of Kp-10 treatment), remained stable for up to at least 10
minutes and decreased thereafter (Fig. 1E, F).
GPR54 activates ERK1/2 in a b-arrestin-dependent
manner
To begin assessing the effect of b-arrestin-1 and -2 in regulating
the GPR54-dependent activation of ERK in MEFs, we began by
determining whether there was any detectable change in pERK
levels in the b-arrestin-1/2 double knockout (b-arr1/2 KO) MEFs
relative to its WT parental MEFs (WT2). GPR54 overexpressing
b-arrestin-1/2 KO MEFs and its WT parent were treated with
Kp-10 (100 nM) for 5, 10, 30 and 60 minutes following which
pERK1/2 levels were assessed by western blotting. Our results
revealed that a loss of b-arrestin-1/2 expression led to significantly
reduced (P,0.01) pERK levels relative to its WT parent at 5 and
10 minutes following Kp-10 treatment (Fig. 2A, B). To ensure that
the differences we were observing in ERK activation were not due
to differences in FLAG-GPR54 expression levels between the KO
cells and their WT parental control cells, we routinely western
blotted for FLAG-GPR54 expression using an anti-DDK (FLAG)
monoclonal antibody. Our data showed that receptor expression
was similar between the KO and control cell lines (Fig. 2C).
Finally, although the levels of pERK1/2 we observed in the
GPR54 overexpressing b-arrestin-1/2 KO MEFs were reduced at
5 and 10 minutes compared to their wild-type parental MEFs,
there is still a significant increase (P,0.01) above basal in ERK1/2
activation in the b-arrestin-1/2 KO cell line at 5 and 10 minutes
Kp-10 treatment (Fig. 2A, B).
Mechanisms of GPR54 Signaling
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of b-arrestin-1
Since it is established that b-arrestin-1 and -2 exert multiple
effects on ERK activation [18], we next assessed the relative
contribution of each isoform on GPR54-dependent ERK activation
beginning with b-arrestin-1.Hereweobservedthat followingKp-10
treatment, the pERK levels in both the GPR54 overexpressing b-
arrestin-1 KO and WT parental MEFs (WT1) increased above
basal at 5 (P,0.01) and 10 minutes (P,0.01) Kp-10 treatment.
Interestingly, relative to its WT parental MEFs, pERK levels were
also significantly higher (P,0.05) at 5 and 10 minutes following Kp-
10 treatment (Fig. 3A, B). At 30 and 60 minutes, however, pERK
levels werethe same between the b-arrestin-1 KO and WT parental
MEFs. As we had demonstrated before, here we also determined
and demonstrated by western blotting that the differences we were
observing in ERK activation were not due to differences in FLAG-
GPR54 expression levels between the KO cells and their WT
parental control cells (Fig. 3C). To confirm the observed differential
ERK activation, we then conducted a b-arrestin-1 ‘add-back’
experiment. Here, GPR54 overexpressing b-arrestin-1 KO MEFs,
co-transfected with either GFP vector (grey bars) or b-arrestin1-
GFP (white bars), were stimulated with 100 nM Kp-10 and then
assessed for ERK1/2 activation, FLAG-GPR54, and b-arrestin1-
GFP expression by western blotting (Fig. 3D). Consistent with the
above findings, we observed that co-expression of FLAG-GPR54
withb-arrestin1-GFP resulted in a significant decrease in pERK1/2
levels following 5 (P,0.05) and 10 minutes (P,0.01) Kp-10
treatment, relative to b-arrestin-1 KO MEFs co-expressing
FLAG-GPR54 and GFP vector (Fig. 3E)
GPR54 positively regulates ERK1/2 activation in a b-
arrestin-2-dependent manner
Next, we examined the relative contribution of b-arrestin-2 in
GPR54 activation of ERK1/2. The data showed that visually,
pERK levels in the b-arrestin-2 KO MEFs increased only slightly
above basal following Kp-10 treatment and this was in marked
contrast to the WT parental cells (Fig. 4A, B). However, when
quantified, this was not significant. Next, we again determined and
demonstrated by western blotting that the differences we were
observing in ERK activation were not due to differences in FLAG-
Figure 1. GPR54 is coupled to ERK MAPK pathway in WT MEFs. Representative autoradiographs (A and C) and densitometric analyses (B and D)
showing the expression of total and activated ERK1/2 in GPR54 overexpressing WT1 (b-arrestin-1 KO parent) and WT2 (b-arrestin-2 and 1/2 KO parent)
MEFs following 10-minute treatment with increasing concentrations of Kp-10 (0–1000 nM). Representative autoradiograph (E) and densitometric
analysis (F) showing the expression of total andactivated ERK1/2 in GPR54 overexpressing WT1 andWT2 parental MEF cell lines following 100 nM Kp-10
treatment (for the indicated time points: 0, 5, 10, 30 and 60 minutes). Western blot analyses were done using monoclonal anti-ERK1/2 and anti-phospho
ERK1/2 antibodies. The data represent the mean 6 S. E. of 4 independent experiments. *P,0.05; **P,0.01vs control (0 min.).
doi:10.1371/journal.pone.0012964.g001
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parental control cells (Fig. 4C). Additionally, to ensure that the
inability of the b-arrestin-2 KO line to stimulate a significant
increase in pERK following Kp-10 treatment was not due to a
general defect in ERK activation by this KO line, we
demonstrated that EGF (10 ng/ml) was able stimulate robust
ERK activation following 10 minutes of stimulation while Kp-10
was unable to at that corresponding time point (Fig. 4D vs. 4A).
We also conducted a b-arrestin-2 ‘add-back’ experiment to
confirm our results. Here, GPR54 overexpressing b-arrestin-2
KO MEFs, co-transfected with either GFP vector (grey bars) or b-
arrestin2-GFP (white bars), were stimulated with 100 nM Kp-10
and then assessed for ERK1/2 activation, FLAG-GPR54, and b-
arrestin2-GFP expression by western blotting (Fig. 4E). Consistent
with the above findings, we observed that co-expression of FLAG-
GPR54 with b-arrestin2-GFP resulted in a significant increase
(P,0.05) in pERK1/2 levels at 5 and 10 minutes Kp-10
treatment, relative to b-arrestin-2 KO MEFs co-expressing
FLAG-GPR54 and GFP vector (Fig. 4F).
GPR54 positively regulates ERK1/2 activation in a Gq/11-
dependent manner
SinceGq/11coupled receptors activate ERK robustly via the Gq/11
pathway, we determined the role of the Gq/11coupled pathway in
the GPR54-dependent activation of ERK. GPR54 overexpressing
Gq/11 KO MEFs and its WT parent were treated with Kp-10
(100 nM) for 5, 10, 30 and 60 minutes following which pERK1/2
levels were assessed by western blotting. The results were very
similar to that observed for the b-arrestin-2 KO MEFs. That is,
visually, pERK levels in the Gq/11 KO MEFs increased only
slightly above basal following Kp-10 treatment and this was in
marked contrast to the WT parental cells (Fig. 5A, B). Again,
when quantified, this was not significant. Next, by western
blotting, we confirmed that differences we were observing in ERK
activation between the KO cells and their WT parental control
cells were not due to differences in FLAG-GPR54 expression
levels (Fig. 5C). To confirm that the inability of the Gq/11 KO
MEFs to trigger a strong response in ERK activation following
Kp-10 treatment was not due to a general defect in ERK
Figure2.GPR54activates ERK1/2inab-arrestin-dependentmanner. Representative autoradiograph(A)anddensitometricanalysis (B)showing
the expression of total and activated ERK1/2 in GPR54 overexpressing b-Arr1/2 double KO (b-Arr1/2 KO) and corresponding wild type parental (WT2)
MEFs following stimulation with 100 nM Kp-10 (for the indicated time points). (C) Representative Western blot confirming absence and presence of
expression of FLAG-GPR54 in non-electroporated (NT) and FLAG-GPR54 overexpressing b-Arr1/2 KO and WT2 MEF cells, respectively. Western blot
analyses were done using monoclonal anti-ERK1/2, anti-phospho ERK1/2, and anti-DDK (FLAG) antibodies. The data represent the mean 6 S. E. of 4
independentexperiments.
##P,0.01vs0 min.control (within the specificcellline).**P,0.01vsrespective wild-typecontrolattheindicatedtimepoint.
doi:10.1371/journal.pone.0012964.g002
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EGF treatment was able stimulate robust ERK activation while
Kp-10 was unable to at that corresponding time point (Fig. 5D vs.
5A). Once again, we conducted a Gq ‘add-back’ experiment to
confirm our results. Here, GPR54 overexpressing Gq/11 KO
MEFs, co-transfected with either GFP vector (grey bars) or Gq
(white bars), were stimulated with 100 nM Kp-10 and then
assessed for ERK1/2 activation, FLAG-GPR54 and Gq expres-
sion by Western blotting. Consistent with the above findings, we
observed that co-expression of FLAG-GPR54 with exogenous Gq
resulted in a significant increase (P,0.01) in pERK1/2 levels at 5
and 10 minutes Kp-10 treatment, relative to Gq/11 KO MEFs co-
expressing FLAG-GPR54 and GFP vector (Fig. 5F).
b-arrestin-2 and Gq/11 regulate the GPR54-dependent
ERK1/2 activation in a very rapid and temporally
overlapping manner
Thus far, our analyses examined GPR54-dependent ERK
activation following 5, 10, 30 and 60 minutes of Kp-10 treatment.
However, since it was demonstrated for the AT1AR that G
protein activation of ERK peaks as early as two minutes following
Figure 3. GPR54 stimulation of ERK1/2 is enhanced in the absence of b-arrestin-1. Representative autoradiograph (A) and densitometric
analysis (B) showing the expression of total and activated ERK1/2 in GPR54 overexpressing b-Arr1 KO and corresponding wild type parental (WT1)
MEFs following stimulation with 100 nM Kp-10 (for the indicated time points). (C) Representative western blot confirming absence and presence of
expression of FLAG-GPR54 in non-electroporated (NT) and FLAG-GPR54 overexpressing b-Arr1 KO and WT1 MEFs, respectively. Representative
autoradiograph (D) and densitometric analysis (E) showing the expression of total and activated ERK1/2 following stimulation with 100 nM Kp-10 (for
indicated time points) of FLAG-GPR54 overexpressing b-Arr1 KO MEFs co-transfected with either GFP vector (grey bars) or b-Arr1-GFP (white bars). All
western blot analyses were done using monoclonal anti-ERK1/2 and anti-phospho ERK1/2 antibodies. Monoclonal anti-b-Arr1 and anti-DDK (FLAG)
antibodies were also used. The data represent the mean 6 S. E. of 4 independent experiments (B) or the mean 6 S. E. of 3 independent experiments
(E).
#P,0.05,
##P,0.01 vs 0 min. control (within the specific cell line). *P,0.05, **P,0.01 vs respective wild-type (or ‘add-back’) control at the
indicated time point.
doi:10.1371/journal.pone.0012964.g003
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b-arrestins on very early ERK activation following 1 and 2.5
minutes of Kp-10 treatment. The data revealed that as early as 2.5
minutes following Kp-10 treatment, significantly reduced pERK
levels were detected in the b-arrestin-2 (P,0.05) and Gq/11
(P,0.05) KO cells compared to their corresponding wild-type
parental cell lines (Fig. 6B, C). At these early time points, b-
arrestin-1 did not have an effect on ERK activation following Kp-
10 treatment (Fig. 6A). Thus it appears that b-arrestin-2 and Gq/11
regulate the GPR54-dependent activation of ERK in a very rapid
and temporally overlapping manner.
Gq/11 and b-arrestin-dependent GPR54-coupled
pathways regulate the spatial distribution of pERK
While immunoblotting of pERK following Kp-10 treatment
provides powerful data on pERK cellular levels it does not provide
any information on the spatial distribution of pERK within the
cell. Therefore, to complement the earlier studies, we conducted a
Figure 4. GPR54 positively regulates ERK1/2 activation in a b-arrestin-2-dependent manner. Representative autoradiograph (A) and
densitometric analysis (B) showing the expression of total and activated ERK1/2 in GPR54 overexpressing b-Arr2 KO and corresponding wild type
parental (WT2) MEFs following stimulation with 100 nM Kp-10 (for the indicated time points). (C) Representative Western blot confirming absence
and presence of expression of FLAG-GPR54 in non-electroporated (NT) and FLAG-GPR54 overexpressing b-Arr2 KO and WT2 MEFs, respectively. (D)
Representative western blot showing the expression of total and activated ERK 1/2 following treatment of the b-Arr2 KO and corresponding wild type
parental (WT2) MEFs with 10 ng/ml EGF (for the indicated time point). This was used as a control to assess whether the ERK1/2 pathway was still
functional in these cells. Representative autoradiograph (E) and densitometric analysis (F) showing the expression of total and activated ERK1/2
following stimulation with 100 nM Kp-10 (for indicated time points) of FLAG-GPR54 overexpressing b-Arr2 KO MEFs co-transfected with either GFP
vector (grey bars) or b-Arr2-GFP (white bars). All western blot analyses were done using monoclonal anti-ERK1/2 and anti-phospho ERK1/2 antibodies.
Monoclonal anti-b-Arr2 and anti-DDK (FLAG) antibodies were also used. The data represent the mean 6 S. E. of 4 independent experiments (B) or the
mean 6 S. E. of 3 independent experiments (F).
##P,0.01 vs 0 min. control (within the specific cell line). *P,0.05, ** P,0.01vs respective wild-type
(or ‘add-back’) control at the indicated time point.
doi:10.1371/journal.pone.0012964.g004
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and b-arrestin KO MEFs and their WT parents before and after
Kp-10 treatment. To do this, we randomly selected a field of view
that had a receptor (GPR54-YFP) expressing and non-expressing
cell. The non-expressing cell served as the control cell. It must be
noted that during the acquisition of image data, the same image
acquisition settings were applied, thus receptor and pERK levels
can be compared between the cell lines and treatments. Visual
analysis of pERK levels yielded data that were in general
agreement with the immunoblot data. The data first revealed
that in the absence of Kp-10 treatment, pERK was barely
detectable in any cell, regardless of whether they expressed GPR54
(Fig. 7). However, following 10 minutes of treatment of all WT
MEFs expressing GPR54, pERK levels increased dramatically
and it was strongly distributed in both the cytosol and nucleus
(Fig. 7). In the b-arrestin-1/2 KO and -1 KO, following treatment,
pERK was also well expressed throughout the cell (Fig. 7).
However, in both the b-arrestin-2 KO and Gq/11 KO cells, pERK
levels were only slightly higher than that observed in untreated
cells (Fig. 7).
Figure 5. GPR54 positively regulates ERK1/2 activation in a Gq/11-dependent manner. Representative autoradiograph (A) and
densitometric analysis (B) showing the expression of total and activated ERK1/2 in GPR54 overexpressing Gq/11 KO and corresponding WT parental
MEFs following stimulation with 100 nM Kp-10 (for the indicated time points). (C) Representative Western blot confirming absence and presence of
expression of FLAG-GPR54 in non-electroporated (NT) and FLAG-GPR54 overexpressing Gq/11 KO and WT MEFs, respectively. (D) Representative
western blot showing the expression of total and activated ERK 1/2 following treatment of the Gq/11 KO and corresponding WT parental MEFs with
10 ng/ml EGF (for the indicated time points). This was used as a control to assess whether the ERK1/2 pathway was still functional in these cells.
Representative autoradiograph (E) and densitometric analysis (F) showing the expression of total and activated ERK1/2 following stimulation with
100 nM Kp-10 (for indicated time points) of GPR54 overexpressing Gq/11 KO MEFs co-transfected with either GFP vector (grey bars) or untagged Gq
(white bars). All western blot analyses were done using monoclonal anti-ERK1/2 and anti-phospho ERK1/2 antibodies. Polyclonal anti-Gq and
monoclonal anti-DDK (FLAG) antibodies were also used. The data represent the mean 6 S. E. of 4 independent experiments (B) or the mean 6 S. E. of
3 independent experiments (F).
##P,0.01 vs 0 min. control (within the specific cell line). *P,0.05, ** P,0.01 vs respective wild-type (or ‘add-back’)
control at the indicated time point.
doi:10.1371/journal.pone.0012964.g005
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continues to modulate gene expression in the absence
of Gq/11
Since our data clearly showed that GPR54 had the capacity to
display G protein-independent signaling by coupling to the b-
arrestin pathway, we tested whether a naturally occurring GPR54
mutant, L148S, which was demonstrated to be functionally
uncoupled from Gq/11 [25] would interact with b-arrestin-1 and
2. Through the use of a co-immunoprecipitation assay, we
demonstrated that it did and that the interaction was also very
robust (Fig. 8A) and identical to what we previously observed for
the interaction between WT GPR54 and b-arrestin-1 and 2 [4].
Next, we reasoned that if L148S could interact with b-arrestin-1
and 2, it might mean that GPR54 molecules could regulate
downstream signaling events like gene expression in the absence of
Gq/11. To test this, Gq/11 KO MEFs expressing FLAG-GPR54
were serum-starved overnight and then treated with Kp-10 for
6 hours in serum-free media. Total RNA was extracted and used
to conduct a microarray analysis of gene expression using the
Affymetrix Mouse Gene 1.0 ST gene array. Our data revealed
that relative to control MEFs, the Gq/11 KO MEFs had a clear
and significant (P,0.05) effect on gene expression following Kp-10
treatment (Fig. 8B). In total, 1,635 (4.6%) out of a total of 35,556
probesets were altered greater than 2-fold (up or down).
GPR54-mediated gene expression in the hypothalamic
cell line, GT1-7, is altered following reduced b-arrestin-1
and 2 expression
Thus far, our studies utilized b-arrestin KO MEFs expressing
exogenous GPR54 to determine the roles of b-arrestin in GPR54
signaling. To complement this study, we also examined the roles of
b-arrestin in regulating gene expression in GT1-7, a hypothalamic
neuronal cell line that expresses GPR54 endogenously [26]. GT1-
7 cell lines stably expressing shRNAs against b-arrestin-1 (line 712)
and b-arrestin-2 (line 153) were created. Western blotting data
revealed that lines 712 and 153 expressed about 50% less b-
arrestin-1 and -2 than the WT parental line expressing scrambled
shRNA sequences (Fig. 9A). WT and b-arrestin-1 and -2
downregulated GT1-7 cells were serum-starved overnight and
then treated with Kp-10 for 6 hours in serum-free media. Total
RNA was extracted and used to conduct a microarray analysis of
gene expression using the Affymetrix Mouse Gene 1.0 ST gene
array. Our analysis revealed that relative to WT GT1-7 expressing
scrambled shRNA sequences, the b-arrestin-1 and -2 downregu-
Figure 6. b-arrestin-2 and Gq/11 regulate the GPR54-dependent ERK1/2 activation in a rapid and temporally overlapping manner.
Representative autoradiographs and densitometric analyses showing the expression of total and activated ERK1/2 in GPR54 overexpressing (A) b-Arr1
KO and WT1 MEFs; (B) b-Arr2 KO and WT2 MEFs; and (C) Gq/11 KO and WT MEFs following stimulation with 100 nM Kp-10 (for the indicated time
points). All western blot analyses were done using monoclonal anti-ERK1/2 and anti-phospho ERK1/2 antibodies. The data represent the mean 6 S. E.
of 3 independent experiments. # P,0.05, ##P,0.01 vs 0 min. control (within the specific cell line). *P,0.05 vs respective wild-type control at the
indicated time point.
doi:10.1371/journal.pone.0012964.g006
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PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12964Figure 7. Gq/11 and b-arrestin-dependent GPR54-coupled pathways regulate the spatial distribution of pERK. Immunofluorescence
analysis of GPR54 expression and pERK levels in GPR54-EYFP overexpressing Gq/11 and b-Arr KO MEFs and their WT parents before and after 10
minutes of Kp-10 treatment. Each inset contains cells that express and do not express GPR54 (green; first and fourth columns). These cells were
analyzed for pERK levels (red fluorescence) before (0 minutes) and after (10 minutes) Kp-10 treatment. Differential interference contrast (DIC) images
of cells and DAPI-stained nuclei (with GPR54 and pERK) are shown to provide greater spatial information. In all cases, the same image acquisition
settings were applied, thus receptor and pERK levels can be compared between cell lines and treatments. The images are representative of 3
independent experiments.
doi:10.1371/journal.pone.0012964.g007
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PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12964lated lines displayed a significantly (P,0.05) different pattern of
gene expression following Kp-10 treatment (Fig. 8B). We also
found that reduced b-arrestin-1 and -2 levels resulted in gene
expression patterns that were higher, lower or unchanged relative
to each other (Fig. 9B).
Discussion
The neuropeptide Kp and its cognate receptor, GPR54 are
major regulators of the HPG axis and loss-of-function mutations in
GPR54 were found to cause an absence of puberty and
hypogonadotropic hypogonadism [2,3]. Despite the physiological
and clinical importance of GPR54, to date only a very small
number of studies have revealed how this receptor signals
intracellularly. Until our recent study where we demonstrated
that GPR54 regulates ERK activity in a b-arrestin-dependent
manner in the invasive breast cancer cell line, MDA MB-231 [4],
it was largely assumed that GPR54-regulated cell functions
occurred via the Gq/11 pathway. Having determined that this
was not the case, we wanted to understand in-depth the
contributions of the GPR54-coupled Gq/11 and b-arrestin
pathways in regulating cell function following Kp treatment. To
do this, we chose ERK activation as our biological readout and
employed the use of MEFs derived from the b-arrestin-1, -2
(single) and -1/2 (double) KO mice as well as the Gq/11 (double)
KO mice [27,28]. Cells derived from these animals have been
used extensively to study the roles of various b-arrestin- and Gq/11
dependent events downstream of multiple GPCRs. For example,
the b-arrestin KO MEFs have been used to study the differential
effects of b-arrestins on the internalization, desensitization and
activation of ERK downstream of protease activated receptor-2
[29] and the roles of b-arrestins in the lysophosphatidic acid-
induced NF-kB activation [30]. The Gq/11 double KO MEFs have
been used to study the bradykinin-mediated MAPK activation
[31] and the regulation of PLCb1a membrane anchoring by its
substrate phosphatidylinositol (4,5)-bisphosphate [32].
Figure 8. L148S interacts with b-arrestin-1 and 2 while GPR54 continues to modulate gene expression in the absence of Gq/11. (A)
Representative autoradiograph showing the co-immunoprecipitation of b-arrestin-1 and b-arrestin-2 with FLAG-L148S. HEK 293 cells were transfected
with 10 mgo fb-arrestin-1 or -2-GFP and 10 mg of FLAG-L148S or empty FLAG vector. Cells were left untreated or stimulated with 100 nM Kp-10 for 5
minutes. Lysates were prepared, immunoprecipitated with mouse anti-FLAG antibody, and immunoblotted with mouse anti-GFP antibody. The
expression of b-arrestin-1 or -2-GFP in 50 mg of total protein from the corresponding HEK 293 cell lysates is also shown. The data represent the mean
6 SE for three independent experiments. IB: Immunoblotting; IP: immunoprecipitation. (B) Gene microarray analysis of Gq/11 KO MEFs versus WT
control MEFs that were treated with Kp-10 for six hours. The data is presented as a three-way Venn diagram and shows the overlap of genes
changing greater than 2 fold in their expression (up or down) as a proportion of all the probesets on the Affymetrix Mouse Gene 1.0 ST Array. In total,
1,635 out of a total of 35,556 probesets are altered greater than 2-fold (4.6%) (P,0.05).
doi:10.1371/journal.pone.0012964.g008
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concentration on ERK activation and found that identical to what
Kotani et al. [1] observed for human GPR54 expressed in CHO-
K1 cells, as little as 10 nM Kp-10 could trigger ERK activation in
the b-arrestin-1 and -2 WT MEFs with a saturable effect being
achieved with 100 nM Kp-10. Next we demonstrated that in the
WT MEFs, 100 nM Kp-10 triggered an early (within 5 minutes)
and robust response in ERK activation that was greatly
diminished within 30 minutes. The rapid activation in ERK was
similar to that described in CHO-K1 cells stably expressing
GPR54 [1]; in COS-7 cells transiently expressing GPR54 [24] and
in GT1-7 mouse hypothalamic neurons expressing endogenous
GPR54 [31]. The diminished response in ERK activation in the
WT MEFs was almost identical to that observed in the GT1-7
neurons [33] and similar to that seen in the COS-7 cells [24].
However, unlike what we observed in the WT MEFS, Kotani
Figure 9. GPR54-mediated gene expression in the hypothalamic cell line, GT1-7 is altered following reduced b-arrestin-1 and 2
expression. (A) GT1-7 cell lines stably expressing shRNAs against b-arrestin-1 (line 712) and b-arrestin-2 (line 153) were created and b-arrestin
expression was determined by western blotting. This data revealed that lines 712 and 153 expressed about 50% less b-arrestin-1 and -2 than the WT
parental line expressing scrambled shRNA sequences. (B) Unsupervised heirarchical clustering showing alterations of gene expression in the GT1-7
lines (712 and 153) relative to wild type. ANOVA was used to determine those probesets changing significantly (P,0.05) at least 1.5 fold in 712 and/or
153 versus WT. This list was then subjected to heirarchical clustering using the average linkage algorithm and displayed as a heat map (representative
samples shown). Red: high expressor, blue: low expressor. Color scale: log(BASE 2) normalized intensity.
doi:10.1371/journal.pone.0012964.g009
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PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e12964et al. (2001) [1] continued to observe very high levels of Kp-10-
dependent ERK activity after 30 minutes in CHO-K1 cells. These
results therefore reveal that GPR54 is functionally coupled to
ERK activation in MEFs and the characteristics of this activation
are similar to that observed in other cellular systems expressing
both endogenous and exogenous GPR54.
The b-arrestin and Gq/11 KO MEFs have proven to be highly
effective cell models for studying the role of b-arrestin and Gq/11 in
the activation of MAPK by various GPCRs [19;29,31]. Here,
based on our findings, we also demonstrate that these cell lines are
a robust model for studying the contributions of the GPR54-
coupled Gq/11 and b-arrestin pathways in mediating ERK
activation. Once this was established, we began by determining
what effect a loss of b-arrestin expression would have on GPR54-
dependent ERK activation in MEFs. Our data showed that a loss
of both b-arrestin-1 and -2 triggered a reciprocal effect on ERK
activation (b-arrestin-2 potentiates and b-arrestin-1 inhibits). This
finding is consistent with findings previously reported for the
AT1AR in HEK-293 cells [9] and suggested for the V2R [20]. A
reciprocal effect has also been documented for PAR1, however,
here b-arrestin-2 inhibits and b-arrestin-1 potentiates ERK
activation [34]. Reciprocal regulation is not mechanistically
understood, nor does it apply to all 7TMRs. For example, the
b2AR and PTH1R exhibit a marked reduction in ERK activation
following siRNA depletion of either b-arrestin1 or -2 [10,13].
Our assessment of the role of the Gq/11 pathway in the GPR54-
dependent activation of ERK reveals that GPR54 simultaneously
requires Gq/11 and b-arrestin-2, as early as 2.5 minutes following
Kp-10 treatment, to trigger maximum ERK activation. Based on
RNAi studies examining ERK activation downstream of the
AT1AR, b2AR, V2R and PTH1R in HEK 293 cells [9,10,13,20],
the Gq/11 and b-arrestin-mediated ERK pathways are temporally
distinct and independent of each other. However, for the
chemokine receptor CCR7, CXCR4, lysophosphatidic acid
receptor and the AT1AR, b-arrestin-dependent signaling was
demonstrated to be dependent on Gi signaling since pertussis toxin
treatment eliminated or reduced the b-arrestin-dependent signal-
ing events [33–37]. Due to the design of these studies the temporal
aspects of the Gq/11 and b-arrestin-mediated signaling events
could not be addressed. In 2005, however, Barnes et al. [22]
demonstrated that the AT1AR-dependent activation of RhoA
requires the concurrent cooperation of the Gq/11 and b-arrestin-1-
dependent pathways. In this study they observed that neither
pathway alone was sufficient to robustly activate RhoA, however,
the concurrent recruitment of b-arrestin-1 and activation of Gq/11
led to full activation of RhoA and to the subsequent formation of
stress fibers. This led them to conclude that both pathways were
co-dependent with respect to RhoA activation.
Finally, both the immunoblot and immunofluorescence analyses
of pERK levels in the cell following Kp-10 treatment were in
general agreement with each other and when considered together,
the biochemical and immunofluorescence data strongly suggest
that downstream of GPR54, b-arrestin-1 negatively regulates the
nuclear accumulation of pERK while b-arrestin-2 and Gq/11 are
simultaneously required for pERK nuclear localization. Therefore,
both Gq/11 and b-arrestins presumably regulate ERK-dependent
gene transcription by directly regulating the nuclear level of
pERK.
Based on our data, we also conclude that GPR54 couples to the
Gq/11 and b-arrestin pathways in a co-dependent and temporally
overlapping manner to regulate ERK activity. While this co-
dependence is significant, it is not absolute, since loss of either Gq/11
or b-arrestin-2 results in a greatly diminished but not a complete
loss of ERK activation. Recently, we reported that GPR54 couples
to b-arrestin-2 via sequences in its second intracellular loop [4] and
another study reported that the L148 residue in the second
intracellular loop of GPR54 is required for the activation of Gq/11
[25]. Taken together, it is possible that Gq/11 and b-arrestin-2 might
be interacting with each other on the second intracellular loop and
this interaction might account for the observed co-dependence.
With respect to the temporal overlap, for many 7TMRs, b-arrestin
only interacts with the receptor following receptor/G protein
interaction. However, we recently reported that GPR54 is
constitutively associated with b-arrestin-1 and -2 [4], thus the
temporal overlap between the GPR54-coupled Gq/11 and both b-
arrestin pathways is consistent with this observation.
To date, a number of naturally occurring GPR54 ‘‘loss-of-
function’’ mutants have been identified [38]. These mutants are
associated with the condition of hypogonadotropic hypogonadism
(HH) in humans and have also been demonstrated to be
uncoupled from the Gq/11 pathway, as evidenced by their inability
to stimulate inositol phosphate formation [38]. We recently
determined that the GPR54 mutant, R331X, is uncoupled from
this pathway because it is not expressed at the plasma membrane
[4]. Using L148S, a functionally Gq/11uncoupled GPR54 mutant
that is still expressed at the plasma membrane [25], we
demonstrated it could still interact with b-arrestins, a strong
indication it and other such mutants are capable of signaling
independently of Gq/11. Next, we demonstrated that even when
uncoupled from Gq/11, GPR54 continues to strongly modulate the
expression of many genes. Taken together, our data implies that
while many naturally occurring GPR54 mutants are uncoupled
from the Gq/11 pathway, they are only ‘‘loss-of-function’’ mutants
with respect to this pathway. This finding, if recapitulated in
physiologically relevant cells, will be potentially significant for both
the mutant and WT receptor. For the mutant receptor it begs the
question as to what roles this receptor continues to play in the HH
individual. For the WT receptor it opens up the possibility of
developing ligand-directed signaling therapies to promote or
reduce certain receptor mediated events, under both healthy and
pathophysiological conditions as has been demonstrated for the b-
adrenergic receptor [39].
Most of our conclusions in this study are based on findings made
in KO MEFs expressing exogenous levels of GPR54. It therefore
remains possible that our results, though fully valid, are specific to
these cells only. Since GPR54 is expressed on GnRH neurons in
the hypothalamus and is best understood as a regulator of
hypothalamic GnRH release [3], we tested the hypothesis, based
on data derived from the KO MEFs that diminished b-arrestin 1
and 2 signaling in the GnRH neuron results in altered downstream
responses, such as gene expression. If this was the case it would
confirm a role for b-arrestin in regulating GPR54 signaling. We
tested our hypothesis in the GT1-7 cell system. GT1-7 is a
neuronal cell line derived from the mouse hypothalamus; it
expresses GPR54 endogenously and is an established neuronal
model for studying GPR54 signaling in the hypothalamus,
specifically as it relates to triggering GnRH release [26]. As
predicted, our data revealed that a loss of b-arrestin-1 and -2
expression in GT1-7 triggered significant and distinct patterns of
responses (increased, decreased and no change) in gene expression
following Kp-10 treatment, thereby confirming b-arrestin-1 and -2
are major mediators of GPR54 signaling. Recently another study
also highlighted possible differential roles for b-arrestin-1 and -2 in
regulating GPCR function in neurons. In a recent study conducted
in hippocampal neurons, Lelouvier et al. [42] demonstrated by
live-cell imaging that following the activation of the somatostatin
type 2A receptor (SST2A), b-arrestin-1 and -2 were recruited to
the plasma membrane but that b-arrestin-1 also translocated to the
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messenger’’ for the SST2A receptor in hippocampal neurons.
GPR54 is a 7TMR of tremendous physiological and clinical
importance. Although, first identified in 1999 as an orphan
receptor [40], the signaling potential of this receptor is gradually
being uncovered. In 2009, our group was the first to demonstrate
that GPR54 undergoes GRK-dependent desensitization; can
recruit and interact with b-arrestin and activate ERK in a b-
arrestin-dependent manner [4]. This finding was significant since
it opened up the possibility that some GPR54-regulated functions
are b-arrestin-dependent. The present study now very convinc-
ingly confirms this. Overall, our studies highlight the importance
of b-arrestin in regulating 7TMR signaling in MEFs, GT1-7
hypothalamic neurons and as we previously reported in MDA
MB-231 human breast cancer cells [4]. Thus it appears that the
GPR54 signaling mechanisms uncovered in this study might be
conserved in various cellular systems.
Materials and Methods
Materials
Restriction enzymes were obtained from New England Biolabs
Inc. (Pickering, ON, Canada). Kisspeptin-10 was purchased from
Phoenix Pharmaceuticals (Burlingame, CA). Rabbit monoclonal
anti-ERK1/2 and anti-phospho ERK1/2 antibodies were from
Cell Signaling Technology (Pickering, ON, Canada). Mouse
monoclonal anti-DDK (FLAG) antibody was obtained from
Origene (Rockville, MD). Mouse monoclonal b-arrestin-1 and -2
antibodies were obtained from Upstate Biotechnology (Lake
Placid). Rabbit polyclonal anti-Gq antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA). Alexa Fluor 568-conjugated anti-
rabbit IgG secondary antibody and Hoechst dye were acquired
from Invitrogen (Burlington, ON, Canada). Fetal bovine serum
and all other cell culture reagents were purchased from Invitrogen
(Burlington, ON, Canada). All other reagents were purchased
from BioShop, Fisher Scientific, VWR, GE and Corning.
Cell Lines
Mouse embryonic fibroblast (MEF) cell lines derived from the b-
arrestin-1 and b-arrestin-2 single and b-arrestin-1/2 double
knockout mice were developed in the laboratory of Dr. Robert
Lefkowitz [27]. The b-arrestin-2 single and b-arrestin-1/2 double
knockout mice were derived from the same WT strain and
accordingly, the same WT MEFs (referred to as WT2) serve as
their WT parents in this study. MEF Gq/11 knockout and wild-
type cell lines were developed in the laboratory of Dr. Stefan
Offermanns and previously described in [28]. The GT1-7 cells
were obtained from Drs. Denise Belsham (University of Toronto)
and Pamela Mellon (University of California, San Diego) [41].
Plasmid Constructs
A 1607-bp cDNA clone encoding human GPR54 was
purchased from Origene (NM_032551.3) and used as a template
to amplify the 1197-bp ORF by PCR. The FLAG-epitope,
engineered into 59 primer sequences, was introduced at the amino
terminus of GPR54 by PCR. FLAG-GPR54 was then cloned into
the NheI and NotI sites of a homemade mammalian expression
vector derived from the pEGFP-C vector backbone (Invitrogen).
The 1197-bp ORF was also cloned into the BglII and HindIII sites
of pEYFP-N1. For the ‘add-back’ experiments, b-arrestin-1-GFP
and b-arrestin-2-GFP were used. The nature of these constructs
was previously described in Pampillo et al., 2009. The Gaq cDNA
(human) was obtained from Dr. Stefan Offermanns.
Cell Culture and Electroporation
MEF b-arrestin-1 knockout, b-arrestin-2 knockout, b-arrestin-
1/2 double knockout, Gq/11 knockout and the corresponding wild
type parental cell lines were all maintained in DMEM supple-
mented with 10% FBS, 1% penicillin/streptomycin (v/v) and 1%
(v/v) non-essential amino acids. GT1-7 cells were grown in
monolayer in DMEM supplemented with 10% FBS, 4.5 mg/ml
glucose and 1% penicillin/streptomycin (v/v). All cell lines were
maintained at 37uC in a humidified atmosphere containing 5%
CO2. When confluent, all MEF cell lines were transiently
transfected with either 20 mg of FLAG-tagged GPR54 (FLAG-
GPR54) or EYFP-tagged GPR54 (GPR54-EYFP) cDNA by
electroporation using the Bio-Rad Gene Pulser Xcell System
(exponential decay protocol: 230 V, 950 mF) with BioRad 0.4 cm
electroporation cuvettes. For the b-arrestin and Gq ‘add-back’
experiments, the appropriate MEF knockout cell lines were co-
transfected with 15 mg of FLAG-GPR54 and 20 mg of either b-
arrestin1-GFP, b-arrestin2-GFP, Gq, or GFP vector (control)
cDNA using the same electroporation protocol described above.
Following electroporation (16–18 hours), cells were split to 6-well
plates (ERK1/2 activation assays) or 18 mm glass coverslips in 12
well plates (immunostaining). The cells were then allowed to
recover for approximately 6 hours prior to overnight serum
starvation in serum-free media.
Generation of b-arrestin-1 and -2 shRNA downregulated
GT1-7 (mouse) cell lines
GT1-7 neurons were transfected with shRNAs (OriGene
Technologies) against b-arrestin 1 (sequence cloned in the
pGFP-V-RS Vector: GACTCCAGTAGACACCAATCTCATA-
GAGC) and b-arrestin 2 (sequence cloned in the pGFP-V-RS
Vector: GTGGCTCAGCTAGAACAAGATGACCAGGT) using
Lipofectamine (Invitrogen) to create the stable cell lines GT1-7
712 and 153, respectively. Heterogeneous populations of stable
transfectants were selected in media containing 0.5 mg/mL of
puromycin and maintained on media containing 0.25 mg/mL of
puromycin. b-arrestin knockdown was confirmed by western blot
analysis.
Western Blot Analysis of ERK1/2 Phosphorylation
MEF knockout (b-arrestin-1KO, -2KO, and -1/2 KO; Gq/11
KO) and wild-type cell lines overexpressing FLAG-GPR54 were
used in ERK1/2 activation assays. Prior to experimentation,
overnight serum-starved wild-type or knockout MEF cells were
placed in Hanks’ balanced salt solution (HBSS: 1.2 mM KH2PO4,
5 mM NaHCO3, 20 mM HEPES, 11 mM glucose, 116 mM
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, pH 7.4) for
30 minutes. Assays were then conducted by treating these cells
with Kp-10 for the indicated times (see figures). Following
stimulation, cells were placed on ice then solubilized in lysis buffer
(25 mM HEPES, pH 7.5, 300 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.1% Triton X-100) containing both protease
inhibitors (AEBSF, leupeptin, aprotinin) and phosphatase inhib-
itors (sodium fluoride, sodium orthovanadate), and then clarified
by centrifugation for 20 minutes at 23 000 RCF. 50 mg of protein
was subjected to SDS-PAGE and subsequently transferred to
nitrocellulose membranes for immunoblotting. Immunoblots were
then analyzed for phosphorylated ERK1/2 using a phosphospe-
cific rabbit monoclonal antibody (1:2,000) (Phospho p44/42
MAPK, Thr202/Tyr204) from Cell Signaling Technology and
for total ERK1/2 using a rabbit monoclonal antibody (1:2,000)
(p44/42 MAPK) from Cell Signaling Technology. Chemilumi-
nescent detection was performed using an anti-rabbit horseradish
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with ECL (GE Healthcare, Piscataway, NJ). Immunoblots were
quantified by densitometry using the 4.0.2 version of the data
acquisition and analysis software from Scion Corp. (Frederick,
MD).
Co-immunoprecipitation
Transiently transfected (FLAG-L148S and b-arrestin 1-GFP or
b-arrestin 2-GFP) HEK 293 cells were serum starved for 30 mins
in HBSS at 37uC and then stimulated with 100 nM Kp-10 for
5 mins. Cells were then solubilized in lysis buffer containing
protease inhibitors. FLAG-L148S was immunoprecipitated from
750 mg of total protein with FLAG-agarose beads (Sigma). The
proteins were analyzed by SDS-PAGE and western blotting as
described in the figure legends. Immunoblots were visualized by
chemiluminescence using an ECL kit.
Confocal Microscopy and Immunostaining
Transiently transfected MEF knockout and wild-type cells
overexpressing GPR54-EYFP were used in the ERK1/2 localiza-
tion studies. Following overnight serum starvation, all cells were
placed in HBSS for 30 minutes and then treated with Kp-10 or
HBSS (vehicle) for 10 minutes. Cells were fixed and permeabilized
using 4% formaldehyde and 0.2% Triton-X in HBSS for 20
minutes before the addition of primary antibody. Cells were
incubated with the phosphospecific ERK1/2 rabbit monoclonal
antibody (1:300) (Phospho p44/42 MAPK, Thr202/Tyr204)
overnight at 4uC, followed by incubation with secondary antibody
(goat anti-rabbit antibody conjugated to AlexaFluor 568 was used
at 1:1200) for 45 minutes at room temperature. Cells were then
counter-stained using Hoechst at 1:50000 (v/v) for 7 minutes at
room temperature to detect nuclei. All coverslips were mounted in
IMMU-MOUNT (Thermo Shandon, Pittsburgh, PA) onto glass
slides and allowed to air dry before viewing. Confocal analysis was
performed on an Olympus Fluoview 1000 laser scanning confocal
microscope using the 40 X Plan Superapochromat 0.9 and the
60X Plan Apochromat 1.42 oil objective. Confocal imaging studies
were performed using multiple excitation (405, 515 and 559) and
emission (band pass 425–475 nm, 530–630 nm and 575–675 nm
for Hoechst, EYFP and AlexaFluor 568 respectively) filter sets.
Multi-colour images were acquired in the sequential acquisition
mode to avoid cross-excitation. During image acquisition, the
same image acquisition settings were applied, thus direct
comparisons could be made between cell lines.
Gene Expression Microarray Analysis
Gq/11 KO MEFs and their WT parents as well as the b-arrestin-
1 and -2 downregulated GT1-7 lines (712 and 153) and their WT
control GT1-7 cells were serum-starved overnight followed by a
wash in HBSS and a second incubation in serum-free media for
one hour. Cells were then treated with Kp-10 for six hours in
serum-free media, following which total RNA was isolated using
the RNeasy Mini Kit from Qiagen (Missassauga, ON, Canada)
according to the manufacturer’s instructions. Total RNA was
subjected to an on column DNase digest to eliminate any possible
genomic DNA contamination using the recommended on column
RNase-free DNase kit (Qiagen). Total RNA was then subjected to
microarray analysis at the London Regional Genomics Centre
(London, ON, Canada). RNA was biotinylated and hybridized to
Mouse 1.0 GST Gene Array (Affymetrix, Santa Clara, CA). Array
washing, scanning and probe quantification were carried out as
per the manufacturer’s instructions using GCOS software [43]
except that the target intensity was set to 150. For each array,
GCOS output was imported as CEL files into Partek Genomic
Suite software (Partek, St. Louis MO), and data were normalized
using the RMA (Robust Multichip Averaging) algorithm. ANOVA
with nominal alpha value set to 0.05 was then used to determine
those probe sets significantly different between the test and control
samples.
Data Analysis
The means 6 S.E are shown for values obtained for the number
of independent experiments indicated in the figure legends.
GraphPad Prism software (Graph Pad, San Diego, CA) was used
to analyze data for statistical significance, as well as to analyze and
fit dose-response data. The statistical significance was determined
by one-way analysis of variance with Dunnett’s multiple
comparison post hoc test and two-tailed t test.
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